Fruquintinib (Fruzaqla, Takeda) is indicated for 'the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy'.
The dosage schedule is available in the summary of product characteristics for fruquintinib.
The list price of fruquintinib is £3,950.00 per 21‑pack of 5‑mg capsules and £790.00 per 21‑pack of 1‑mg capsules (excluding VAT; BNF online accessed June 2025).
The company has a commercial arrangement. This makes fruquintinib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on the company's webpage on sustainability.